2.4. Ethical Considerations
The study received approval from the institutional review board of Partners HealthCare-Brigham and Women’s Hospital. All participants provided written informed consent prior to their enrollment in the trial. The trial agents obtained Investigational New Drug approval from the United States Food and Drug Administration (FDA).